INOVIO Presents CD4+ T‑cell Activation for INO‑3107 in RRP at AACR

INOVIO to Present T‑cell Activation Data for RRP at AACR

INOVIO Pharmaceuticals presents new immune data from its INO‑3107 DNA immunotherapy at the American Association for Cancer Research Immuno‑Oncology Conference in Los Angeles on Feb. 18, showcasing activation of pro‑inflammatory CD4+ T cells in patients with recurrent respiratory papillomatosis (RRP). The company displays a poster titled “Treatment of RRP with DNA immunotherapy INO‑3107 induces activation and enrichment of pro‑inflammatory CD4+ T cell responses in blood and airways of patients with clinical response,” highlighting cellular immune changes associated with clinical benefit.

The data emphasize enrichment of pro‑inflammatory CD4+ T cell responses both systemically and in airway compartments among patients who show clinical responses, supporting INOVIO’s DNA‑based immunotherapy approach to targeting HPV‑driven disease. Company researchers frame these findings as evidence that a targeted DNA vaccine can mobilize the type of T‑cell immunity that is thought to control HPV‑related lesions, a key mechanistic objective for therapies addressing RRP.

INOVIO signals that these results form part of a wider development program aimed at treating HPV‑related conditions through DNA medicines, and the company intends to post full abstracts on its website after presentation. Management also holds that additional analyses and follow‑up discussions with investigators and clinicians at the conference will inform next steps in clinical development for INO‑3107.

Planned presentations on DNA‑based COVID‑era technologies

Beyond RRP data, INOVIO schedules several investor and scientific presentations this spring. It appears virtually at the Oppenheimer Healthcare Life Sciences Conference on Feb. 25 and presents safety and pharmacokinetic findings from a Phase 1 trial of SARS‑CoV‑2 DNA‑encoded monoclonal antibodies (DMAbs) at the Festival of Biologics in San Diego on March 4. The company also takes part in a fireside chat at the Citizens Life Sciences Conference on March 10; webcasts and replays for investor events are available through INOVIO’s events page for 90 days.

Company focus and access to materials

INOVIO reiterates its strategic focus on developing and commercializing DNA medicines for HPV‑related diseases, oncology and infectious diseases and says management will conduct one‑on‑one meetings with investors and peers during the conferences. Abstracts and investor event replays are posted on INOVIO’s website following presentations.